FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine (Q37229935)

19 August 2017

title

FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine (English)

1 reference

19 August 2017

main subject

visceral leishmaniasis

1 reference

1 reference

Irene da Silva Soares

8

object named as

Irene Soares

1 reference

19 August 2017

author name string

Clarisa B Palatnik-de-Sousa

1

1 reference

19 August 2017

André de Figueiredo Barbosa

2

1 reference

19 August 2017

Sandra Maria Oliveira

3

1 reference

19 August 2017

Dirlei Nico

4

1 reference

19 August 2017

Robson Ronney Bernardo

5

1 reference

19 August 2017

Wania R Santos

6

1 reference

19 August 2017

Mauricio M Rodrigues

7

1 reference

19 August 2017

Gulnara P Borja-Cabrera

9

1 reference

19 August 2017

publication date

1 August 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

833-851

1 reference

Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Persistence without pathology in phosphoglycan-deficient Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Investigations on polysaccharide components of cells of Herpetomonas samuelpessoai grown on various media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Visceral leishmaniasis after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Transmission of parasites by blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Vaccines for leishmaniasis in the fore coming 25 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunity and immunosuppression in experimental visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Cell-mediated immunity in experimental cutaneous Leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Leishmania-specific lymphoproliferative responses and IgG1/IgG2 immunodetection patterns by Western blot in asymptomatic, symptomatic and treated dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on the fecundity and mortality of Phlebotomus duboscqi (Diptera: Psychodidae).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-å crystal structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Inosine-uridine nucleoside hydrolase from Crithidia fasciculata. Genetic characterization, crystallization, and identification of histidine 241 as a catalytic site residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Molecular cloning and expression of a purine-specific N-ribohydrolase from Trypanosoma brucei brucei. Sequence, expression, and molecular analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Effects of hydrostatic pressure on the Leptospira interrogans: high immunogenicity of the pressure-inactivated serovar hardjo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.6.833

21 January 2018

Identifiers

DOI

10.1586/14760584.7.6.833

1 reference

19 August 2017

1 reference